Patients were stratified according to a minimisation algorithm by Eastern Cooperative Oncology Group performance status , smoking history , centre , and masked pretreatment serum protein test classification , and randomly assigned centrally in a @:@ ratio to receive erlotinib ( @ mg/day , orally ) or chemotherapy ( pemetrexed @ mg/m ( @ ) , intravenously , every @ days , or docetaxel @ mg/m ( @ ) , intravenously , every @ days ) .